Exact Mass: 362.0837

Exact Mass Matches: 362.0837

Found 67 metabolites which its exact mass value is equals to given mass value 362.0837, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

7-O-Galloyl-sedoheptulose

(2,3,4,5,7-Pentahydroxy-6-oxoheptyl) 3,4,5-trihydroxybenzoate

C14H18O11 (362.0849)

4,5-Diaminofluorescein

5,6-diamino-3,6-dihydroxy-3H-spiro[2-benzofuran-1,9-xanthene]-3-one

C20H14N2O5 (362.0903)

Piretanide

4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid

C17H18N2O5S (362.0936)

D045283 - Natriuretic Agents > D004232 - Diuretics > D049994 - Sodium Potassium Chloride Symporter Inhibitors C - Cardiovascular system > C03 - Diuretics > C03C - High-ceiling diuretics > C03CA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49184 - Loop Diuretic D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators

3',6'-Dihydroxy-4,5-diaminospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-3-one

3,6-Dihydroxy-4,5-diaminospiro[isobenzofuran-1(3H),9-[9H]xanthene]-3-one

C20H14N2O5 (362.0903)

Resomycin C

C21H14O6 (362.079)

Tephcalostan

8,9-Methylenedioxy-5-(1-methylethenyl)-4,5-dihydrofurano[2,3:3,2]-coumestan

C21H14O6 (362.079)

4,5-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3H-furo[2,3,4-kl]pyrrolo[4,3,2-fg][3]benzazocine-3,6(8H)-dionem|calanthumindole

C20H14N2O5 (362.0903)

canaliculatin

C21H14O6 (362.079)

15-methoxyhalenaquinone

C21H14O6 (362.079)

Methyl 18-Bromo-(9Z,15Z,17E)-octadeca-9,15,17-triene-5,7-diynoate

C19H23BrO2 (362.0881)

DAF-2

2-(3,6-dihydroxy-4,5-diamino-9H-xanthen-9-yl)-benzoic acid

C20H14N2O5 (362.0903)

D004396 - Coloring Agents > D005456 - Fluorescent Dyes > D005452 - Fluoresceins D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents

Piretanide

C17H18N2O5S (362.0936)

FR140423

3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole

C18H16F2N2O2S (362.09)

CONFIDENCE standard compound; INTERNAL_ID 660; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8446; ORIGINAL_PRECURSOR_SCAN_NO 8442 CONFIDENCE standard compound; INTERNAL_ID 660; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8470; ORIGINAL_PRECURSOR_SCAN_NO 8469 CONFIDENCE standard compound; INTERNAL_ID 660; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8485; ORIGINAL_PRECURSOR_SCAN_NO 8483 CONFIDENCE standard compound; INTERNAL_ID 660; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8519; ORIGINAL_PRECURSOR_SCAN_NO 8516 CONFIDENCE standard compound; INTERNAL_ID 660; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8520; ORIGINAL_PRECURSOR_SCAN_NO 8517 CONFIDENCE standard compound; INTERNAL_ID 660; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8527; ORIGINAL_PRECURSOR_SCAN_NO 8525

5-(4,4,6-trimethyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)naphthalene-2-sulfonic acid

C17H18N2O3S2 (362.0759)

Methyl 18-bromooctadec-17-en-5,7,15-triynoate

Methyl 18-bromo-17E-octadecen-5,7,15-triynoate

C19H23BrO2 (362.0881)

Methyl 18-bromo-17Z-octadecen-5,7,15-triynoate

C19H23BrO2 (362.0881)

Methyl 18-bromo-9E,15E,17E-octadecatrien-5,7-diynoate

C19H23BrO2 (362.0881)

Methyl 18-bromooctadec-17-en-5,7,15-triynoate

Methyl 18-bromo-17E-octadecen-5,7,15-triynoate

C19H23O2Br (362.0881)

Methyl 18-bromo-17Z-octadecen-5,7,15-triynoate

C19H23O2Br (362.0881)

Methyl 18-bromo-9E,15E,17E-octadecatrien-5,7-diynoate

C19H23O2Br (362.0881)

7-chloro-1-(2,3-dihydroxypropyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one

C18H16ClFN2O3 (362.0833)

Pyrano[2,3-c]pyrazole-5-carbonitrile,6-amino-4-(4-chlorophenyl)-1,4-dihydro-3-methyl-1-phenyl-

C20H15ClN4O (362.0934)

4-[3-(3,4-dicyanophenoxy)phenoxy]benzene-1,2-dicarbonitrile

C22H10N4O2 (362.0804)

4-BENZYLOXY-5-BROMO-2-(4-METHYLPIPERAZIN-1-YL)-PYRIMIDINE

C16H19BrN4O (362.0742)

Piperazine-1,4-bis(2-hydroxypropanesulfonic acid) dihydrate

C10H22N2O8S2 (362.0818)

diphacinone-sodium

C23H15NaO3 (362.0919)

(R)-3-((6,7,8,9-TETRAHYDRO-5H-BENZO[7]ANNULEN-5-YL)THIO)-5-UREIDOISOTHIAZOLE-4-CARBOXAMIDE

C16H18N4O2S2 (362.0871)

1,5-diamino-4,8-dihydroxy(4-hydroxyphenyl)anthraquinone

C20H14N2O5 (362.0903)

Etoricoxib D4

C18H11D4ClN2O2S (362.0794)

disperse blue 35

C20H14N2O5 (362.0903)

Disperse Blue BGL

C20H14N2O5 (362.0903)

Trimethyl[1-(2,6-xylylcarbamoyl)ethyl]ammonium iodide

C14H23IN2O (362.0855)

N-[3-cyano-4-[(4-methylphenyl)thio]phenyl]-4-fluorobenzamide

C21H15FN2OS (362.0889)

1,5-Dihydroxy-4,8-bis(hydroxy(hydroxymethyl)amino)anthraquinone

C16H14N2O8 (362.075)

3-{5-[Amino(iminio)methyl]-6-chloro-1H-benzimidazol-2-YL}-1,1-biphenyl-2-olate

C20H15ClN4O (362.0934)

6-(O-beta-D-glucopyranosyl) camalexin

C17H18N2O5S (362.0936)

5-Chloro-7-[3-pyridinyl-(2-pyridinylamino)methyl]-8-quinolinol

C20H15ClN4O (362.0934)

6-(1,3-benzodioxol-5-yl)-N-(2-thiazolylmethyl)-4-quinazolinamine

C19H14N4O2S (362.0837)

4-chloro-N-[4-[3-(methylthio)anilino]-4-oxobutyl]benzamide

C18H19ClN2O2S (362.0856)

2-[(5-cyano-4-oxo-6-phenyl-1H-pyrimidin-2-yl)thio]-N-phenylacetamide

C19H14N4O2S (362.0837)

8-Chloro-7-[2-(4-methoxyphenyl)-2-oxoethyl]-1,3-dimethylpurine-2,6-dione

C16H15ClN4O4 (362.0782)

Cefadroxil(1-)

C16H16N3O5S- (362.0811)

A cephalosporin carboxylic acid anion having a 7beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino side-chain, formed by proton loss from the carboxy group of the cephalosporin cefadroxil.

BZAD-01

C16H12F6N2O (362.0854)

BZAD-01 is a potent, selective and orally active inhibitor of NMDA NR2B subunit, with a Ki of 72 nM. BZAD-01 can improve postural asymmetry as well as Apomorphine-induced rotation[1].